|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 5 (September 1), 1999:
pp. 1761-1772
Growth Characteristics of Acute Myelogenous Leukemia Progenitors
That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe
Combined Immunodeficient Mice
By
Laurie E. Ailles,
Brigitte Gerhard,
Hiroyuki Kawagoe, and
Donna E. Hogge
From the Terry Fox Laboratory, British Columbia Cancer Agency,
Vancouver, BC, Canada; and the Departments of Medicine and Medical
Genetics, University of British Columbia, Vancouver, BC, Canada.
 |
ABSTRACT |
The use of immunodeficient mice, particularly of the nonobese
diabetic/severe combined immunodeficient (NOD/SCID)
strain, has allowed detection of very primitive malignant progenitors from patients with acute myelogenous leukemia (AML). To define the
sensitivity and reproducibility with which the engraftment of different
AML cells can be detected, 61 different samples from patients with
newly diagnosed AML representing a variety of cytogenetic and
French-American-British (FAB) subtypes were injected into NOD/SCID
mice. Eight weeks after intravenous injection of 107 AML
cells, the average percent of human cells in mouse bone marrow was
13.3%, with 70% of samples showing easily detectable engraftment of
CD45+ cells. AML samples with cytogenetic changes
associated with a poor clinical prognosis tended to engraft to higher
levels than those with changes associated with a good prognosis. Cells
with FAB subtypes M3 and, to a lesser extent, M2, engrafted more poorly (P = .002 and .06, respectively) than those from other
subtypes. Intraperitoneal injection of human interleukin-3 and Steel
factor thrice weekly for 4 weeks did not enhance the levels of AML cell engraftment. However, AML samples that showed cytokine-independent colony growth in methylcellulose assay or expressed growth-factor mRNA
in malignant blasts achieved significantly higher levels of engraftment
than those which were cytokine dependent in culture or failed to
express cytokine message (P < .03 and P < .02, respectively). In 6 patient samples, the frequency of NOD/SCID
leukemia-initiating cells (NOD/SL-IC) varied from 0.7 to 45 per
107 cells, which was 200- to 800-fold lower than the
frequency of AML long-term culture-initiating cells (AML LTC-IC) in the
same samples. Each NOD/SL-IC will produce more than 106
leukemic blasts as well as many AML-CFC and AML LTC-IC as detected 8 weeks postinjection into mice. Serial transplant experiments showed the
ability of NOD/SL-IC to maintain their own numbers over at least 3 to 4 weeks in vivo. The ability of these progenitors to self-renew combined
with their potential to differentiate to produce large numbers of more
mature progenitors and leukemic blasts suggests that the NOD/SL-IC
assay identifies leukemic `stem cells' that may maintain the
malignant clone in human patients. The further use of this assay should
facilitate studies of AML stem cell biology and the evolution of novel
therapeutic strategies.
© 1999 by The American Society of Hematology.
| |
INTRODUCTION |
THE MALIGNANCIES encompassed by the term
acute myelogenous leukemia (AML) are clonal disorders of hematopoiesis
associated with varying degrees of deregulation of normal hematopoietic
differentiation and proliferation. However, despite these defects it
has been possible to show that the hierarchical organization of
progenitor cells that characterizes normal blood cell formation is
preserved to a large extent in these diseases. Thus, a proportion of
leukemic cells will form colonies of blasts in semisolid medium when
supplied with a source of hematopoietic growth factors (AML
colony-forming cells or AML-CFC).1 More recently it has
been shown that leukemic progenitors which are more rare than AML-CFC
can give rise to long-term malignant hematopoiesis when placed in
coculture with supportive feeder layers or in suspension cultures
supplemented with cytokines.2,3 The cell-surface phenotype
of these leukemic long-term culture-initiating cells (AML LTC-IC) or
suspension culture-initiating cells appears to be very similar to
normal LTC-IC.3-5
Transplantation models in mice have been critical to the development of
our understanding of the most primitive hematopoietic progenitors that
are capable of reconstituting multilineage hematopoiesis in lethally
irradiated recipients. It has been possible to use some of the
principles that were used to develop these assays for murine `stem
cells' to study normal human cells that exhibit similar potential when
injected into sublethally irradiated immunodeficient mice. Recent
studies have shown that multilineage human hematopoiesis can be
successfully established in nonobese diabetic/LtSz-scid/scid (NOD/SCID)
mice6 after intravenous (IV) injection of normal human
marrow or cord blood cells.7-11
Immunodeficient mice will also support the growth of malignant
progenitors from patients with chronic myelogenous leukemia and
AML.12-15 IV injection of cells directly isolated from
patients with AML into NOD/SCID mice can result in the engraftment and proliferation of these cells in mouse hematopoietic tissues in a
fashion similar to that seen in the human disease.15 AML
cells with the potential to initiate leukemia in mice (NOD/SCID
leukemia-initiating cells or NOD/SL-IC) are rare progenitors that are
largely CD34++ CD38 ,14,15
CD71 and HLA-DR,16
and Thy-1.17 These results suggested
that NOD/SCID animals could be used for the detection and further
characterization of very primitive leukemic progenitors that may be
analogous to those which maintain the leukemic clone in patients. The
fact that such cells are the obvious targets for novel therapeutic
approaches in AML further supported our efforts to enhance our
understanding of this model system.
Although it was clear from the preceding studies that AML cells would
grow successfully in the appropriate mouse strains, the variability of
the growth potential of various AML samples was not so apparent. In
addition, little was known about factors that may influence growth of
human AML cells in these animals and how various classes of malignant
progenitors were maintained over time in the mice. The current studies
were undertaken to answer several of these questions. Firstly, we
surveyed a large series of AML samples representative of the clinical,
phenotypic, and genetic heterogeneity seen in these diseases for their
ability to grow in NOD/SCID mice. Secondly, the human cytokine
requirements of NOD/SL-IC were studied and compared with both the
growth-factor responsiveness of AML-CFC and autocrine growth-factor
gene expression by the malignant blasts from the same patient specimen.
Thirdly, the frequency and proliferative capacity of NOD/SL-IC was
described and compared with the same parameters obtained for AML
LTC-IC. These data show the ability of NOD/SCID mice to allow the
detection and quantitation of these very primitive leukemic progenitors in most AML samples. Furthermore, clinical features of the disease with
prognostic significance in patients, cytokine gene expression in the
malignant clone, and the growth characteristics of leukemic progenitors
in culture appear to predict the growth potential of NOD/SL-IC from
different cell sources in mice.
| |
MATERIALS AND METHODS |
Patients' cells.
Peripheral blood or bone marrow cells were obtained from 61 patients
(pts) with newly diagnosed AML undergoing marrow and blood examination
for diagnostic purposes after informed consent and with the approval of
the Clinical Research Ethics Board of the University of British
Columbia. Mononuclear cells were separated by Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden) density gradient centrifugation and either
used immediately for the experiments described below or cryopreserved
in Iscove's modified Dulbecco's medium (IMDM; Stem Cell Technologies,
Vancouver, Canada) with 50% fetal calf serum (FCS) and 10%
dimethylsulfoxide. Frozen cells were thawed at 37°C, washed in
 -MEM (Stem Cell Technologies) with 5% FCS, and cell viability was
determined by trypan blue exclusion. As part of their clinical
evaluation, all patient samples had morphological, histochemical, and
flow cytometric studies performed on their leukemic blasts with
subsequent classification according to French-American-British (FAB)
subtypes.18 Cytogenetic analysis was performed on the
initial diagnostic bone marrow samples.
Eleven patient samples were analyzed in more detail than the group as a
whole for their cytokine responsiveness and/or the frequency and
proliferative capacity of malignant progenitors. Clinical
characteristics of these patients at presentation are shown in
Table 1.
Transplantation of AML cells into NOD/SCID mice.
NOD/SCID mice were bred and maintained under sterile conditions in the
British Columbia Cancer Research Center Joint Animal Facility according
to protocols approved by the Animal Care Committee of the University of
British Columbia. Six- to 8-week-old mice were irradiated with 350 cGy
from a 137Cs source 24 hours before injection of patient
AML cells via the tail vein. After various periods of time, mice were
killed by CO2 inhalation. Blood cells were obtained by
cardiac puncture. Bone marrow was removed from the 4 long bones of the
limbs by flushing with -MEM with 5% FCS. Spleen cells were obtained
by mincing and flushing separated cells free with media. Cells from mouse tissues were then used in the assays described below. When human
cytokines were administered to mice they were diluted in sterile
phosphate-buffered saline (PBS) with 0.1% bovine serum albumin (BSA)
and injected intraperitoneally on Monday, Wednesday, and Friday of each
week beginning 4 weeks after injection of AML cells.
Cytokines.
Human interleukin-3 (IL-3) was obtained from Sandoz International
(Basel, Switzerland) and human Steel factor (SF) was purified in our
center from supernatants of COS cells transfected with the cytokine
cDNA. Cytokine levels in mouse serum were determined by enzyme-linked
immunosorbent assay (ELISA) according to the manufacturer's
instructions (R&D Systems, Minneapolis, MN).
Flow cytometry.
Cells from mouse tissues were treated with 7% ammonium chloride (Stem
Cell Technologies) to lyse red blood cells, then spun down and
resuspended in Hanks' balanced salt solution with 2% FCS (HFN) and
5% human serum for blocking of human Fc receptors. Cells were
incubated on ice with an anti-mouse IgG Fc receptor monoclonal antibody
(2.4G2; SyStemix, Palo Alto, CA) for blocking of nonspecific binding to
mouse Fc receptors. Half of each sample was then incubated on ice with
fluoresceinated anti-CD45, a human-specific pan-leukocyte marker
(prepared in our center from American Type Culture Collection [ATCC]
clone no. HB10508, Rockville, MD) to detect human cells, and the other
half with fluoresceinated mouse IgG1(Becton Dickinson Immunocytometry
Systems, San Jose, CA) as an isotype control for nonspecific
immunofluorescence. Finally, cells were stained with 2 µg/mL
propidium iodide in HFN. Flow cytometric analysis was performed on a
Becton Dickinson FACScan or FACSort flow cytometer. A gate was set to
exclude at least 99.9% of cells labeled with the isotype control, and
the percent of CD45+ cells was then determined using the
same gate after excluding nonviable cells. In experiments where bone
marrow cells from control mice that had not been previously injected
with human bone marrow cells were analyzed, the mean ± SEM percent
CD45+ cells was 0.09% ± 0.01%
(n = 30) and the highest level of apparently CD45+ cells
detected in 1 of these 30 control mice was 0.33%. In some experiments,
CD45+ cells were sorted into media and used for functional
assays, fluorescence in situ hybridization (FISH), or morphological analysis.
Histology and FISH.
Bone marrow smears were obtained from mice at the time of killing by
snipping the end off the femur and smearing the cut end on a glass
slide. Alternatively, cytospin preparations were made from bone marrow
cell suspensions or flow-sorted CD45+ cells. Slides were
then fixed in either methanol:acetone (1:3) for 20 minutes for
May-Grünwald-Giemsa staining, or in methanol:acetic acid (3:1)
for FISH as previously described2 to detect the presence of
cytogenetic abnormalities characteristic of the leukemic cells.
Briefly, the probe used to detect the +8 abnormality was the D8Z2
plasmid (ATCC), which is specific for centromeric repeat sequences on
human chromosome 8, and which was labeled with digoxigenin (DIG;
Boehringer Mannheim, Mannheim, Germany) by nick translation. To detect
the +13 abnormality, the Quint-Essential 13-specific DNA probe labeled
with DIG was purchased from Oncor (Gaithersburg, MD). For both probes,
all slides were pretreated as previously described.2 For
the chromosome 8 probe, hybridization and washing conditions were as
previously described; for the chromosome 13 probe, hybridization and
washing conditions were as instructed by the manufacturer. In both
cases, detection of DIG-labeled probes was performed using sheep
anti-DIG-fluorescein isothiocyanate (FITC) antibody (Boehringer
Mannheim) and rabbit anti-sheep-FITC antibody (Vector Labs,
Burlingame, CA), as previously described.2 Finally, slides
were counterstained with 0.5 µg/mL propidium iodide in antifade (200 mmol/L 1,4 diazabicyclo-[2,2,2]-octane, 2 mmol/L Tris, pH 8, in 90%
glycerol) and viewed on a Zeiss Axioplan fluorescence microscope (Zeiss, Oberkochen, Germany) equipped with a
double bandpass filter to allow simultaneous visualization of the FITC signal and the propidium iodide counterstain. In the case of BM smears
or cytospins prepared from unsorted mouse BM, only cells that clearly
had either 2 signals or 3 signals were counted (ie, only human cells).
The number of cells counted in these cases ranged from 5 to 76 per
slide, with the lower end of this range being due to a low engraftment
level in that mouse ( 1%). For CD45+ sorted cells, again
only cells with a clear 2 or 3 signals were counted, and the number of
cells counted ranged from 42 to 85 per slide. In the case of colonies,
each colony was scored as either normal or abnormal only if a minimum
of 5 cells per colony showed a clear signal, and if at least 80% of
the cells in a given colony showed either the normal or the abnormal
signal. The human origin of colonies was confirmed by hybridization
with the human specific FISH probes.
May-Grünwald-Giemsa-stained slides were examined by bright-field
microscopy and a minimum of 200 cells scored for the presence of AML
blasts to obtain percentages for comparison with the results of CD45 analysis.
DNA analysis.
In some cases, the proportion of human cells in mouse tissue was
determined by DNA analysis. Cells from mouse tissue suspended in media
were centrifuged and resuspended in 2 mL of DNA lysis buffer (10 mmol/L
Tris, pH 8.0, 150 mmol/L NaCl, 10 mmol/L EDTA, 0.5% sodium dodecyl
sulfate [SDS], 200 µg/mL proteinase K [Life Technologies,
Gaithersburg, MD]) and incubated at 37°C overnight. Two
equal-volume phenol extractions and 2 equal-volume chloroform:isoamyl alcohol (24:1) extractions were performed, and then DNA was dialyzed for 48 hours, with 3 changes of dialysis buffer (10 mmol/L Tris, 1 mmol/L EDTA, pH 7.5). For Southern blotting, 10 µg of the resulting DNA was digested with 100 U of EcoRI (Life Technologies)
overnight at 37°C, run in a 1% agarose gel, and blotted by
standard procedures.19 Blots were hybridized with a
32P-labeled EcoRI fragment of the human endogenous
retroviral sequence (HERV-H) as a human-specific probe. This DNA
sequence is known to be present at approximately 1,000 copies in the
human genome.20 To estimate the proportion of human cells
in mouse-tissue DNA, a dilution series of human genomic DNA mixed with
mouse DNA, ranging from 0.1% to 100% human DNA, was run on the same
gel as the samples to be evaluated and the intensities of hybridization
signals from the samples compared with that from the known mixtures.
The correlation between the proportion of human cells in mouse tissues
estimated by this method compared with that determined by FACS analysis was .93, P < .001. However, whereas the limit of sensitivity
for FACS analysis was approximately 0.5% human cells, less than 0.1% human cells could be detected using the Southern blotting technique.
Detection of cytokine gene expression in AML blasts.
Total amplified cDNA was generated from AML blasts with an
oligo(dT)-based primer and poly(A) tailing strategy, as
described.5,21 Briefly, total RNA was extracted from
aliquots of 104 cells and reverse transcribed using a
60-mer oligo(dT) primer. The reverse transcription product was then
poly(A)-tailed, and this mixture was polymerase chain reaction
(PCR)-amplified using the oligo(dT) primer, to yield total amplified
cDNA. An aliquot of total amplified cDNA was subjected to Southern
blotting followed by hybridization with probes for human cytokines. To
ensure that cDNA amplification had been successful, each blot was also
hybridized with a  -actin probe.22 Hybridization and
washing conditions were as described.21
To enhance the sensitivity with which growth-factor cDNA could be
detected, a second round of PCR was performed using cytokine-specific primers when Southern blotting of total cDNA did not detect expression of the growth factors. The 50-µL PCR reaction contained 1 µL of total amplified cDNA, 1X PCR buffer containing 20 mmol/L Tris-HCl pH
8.4 and 50 mmol/L KCl (Life Technologies), 1 U of Taq DNA polymerase (Life Technologies), and 10 pmol of each primer, as follows: IL-3 (5'-GCTCCCATGACCCAGACAACGTCC-3') and
(5'-CAGATAGAACGTCAGTTTCCTCCG-3'); SF
(5'-GGATCTGCAGGAATCGTGTGACTA-3') and
(5'-CTTCAGGAGTAAAGAGCCTGGGTT-3'); granulocyte
colony-stimulating factor (G-CSF)
(5'-CTCTGGACAGTGCAGGAAGCCACC-3') and
(5'-GCTGGGCAAGGTGGCGTAGAACGC-3');
granulocyte-macrophage colony-stimulating factor (GM-CSF)
(5'-CGGCGTCTCCTGAACCTGAG-3') and
(5'-CCAGCAGTCAAAGGGGATGA-3'), to give DNA fragments of 345 bp, 335 bp, 547 bp, and 300 bp, respectively. Thirty cycles of 94°C
for 30 seconds, 60°C for 1 minute, and 72°C for 1 minute were
then performed. As a positive control, mouse cell lines that had been
transfected with the appropriate human growth-factor cDNA were analyzed
in parallel. PCR products were gel electrophoresed and transferred onto
a nylon membrane before hybridization with cytokine cDNA probes
(Zeta-probe; BioRad, Hercules, CA).
The following gel-purified fragments were used to synthesize the
probes: the entire 950-bp coding sequence of the human SF cDNA,23 the entire 600-bp coding sequence of the human IL-3 cDNA,24 the 466-bp PstI fragment of the human
GM-CSF cDNA,25 the entire 700-bp coding sequence of the
human G-CSF cDNA,26 and the 1,200-bp PstI fragment
of a chicken -actin cDNA.22 Probes were labeled with
32P-dCTP (Amersham, Arlington Heights, IL) using a
random-primer DNA labeling system (Life Technologies) according to the
manufacturer's instructions and purified on a Sephadex-G50 column
(Pharmacia Biotech, Uppsala, Sweden). Blots were hybridized overnight
at 65°C in 6X SSC,19 1% SDS, 1X Denhardt's solution
(0.02% wt/vol Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA), then
washed twice in 0.3X SSC, 0.1% SDS for 30 minutes each at 65°C,
and exposed to Kodak XAR film (Eastman Kodak, Rochester, NY).
AML-CFC assays.
To quantitate AML-CFC numbers, cells obtained either directly from mice
or after FACS purification of CD45+ cells were plated at a
concentration of 0.2 to 1 × 105 cells/mL in
methylcellulose medium (0.92% methylcellulose, 30% FCS, 2 mmol/L
L-glutamine, 104 mol/L -mercaptoethanol, 1% BSA
in IMDM; Stem Cell Technologies) with 3 U/mL human erythropoietin (Epo;
Stem Cell Technologies), 10 ng/mL GM-CSF (Sandoz), 10 ng/mL IL-3, 50 ng/mL SF, and 50 ng/mL Flt-3 ligand (Immunex, Seattle, WA). Cultures
were scored for the presence of colonies containing more than 20 cells
and clusters of 4 to 20 cells 14 days later. Because it is possible for
some mouse colonies to grow under the conditions of these colony
assays, when cells were assayed directly without FACS purification
colonies were plucked onto glass slides for FISH to determine their
human origin as well as the presence or absence of cytogenetic
abnormalities that were present in the initial leukemic clone.
LTC.
LTC were established as previously described27 by coculture
of mouse bone marrow cells with Sl/Sl-J-IL3 feeders, which consist of
Sl/Sl fibroblasts, originally obtained from Sl/Sl mouse
embryos28 engineered to produce human IL-3 at a
concentration of 16.5 ng/mL. These feeders were irradiated to 80 Gy and
plated in collagen-coated tissue culture dishes at 3 × 104 cells/cm2 at least 24 hours before
coculture. Bone marrow cells from engrafted mice were sorted by FACS
for CD45 expression before coculture with these feeders in cases where
engraftment levels were low (<10%), or were placed directly into
coculture in cases where higher engraftment levels were achieved. Cell
numbers plated ranged from 3 to 8 × 105 per 35-mm
diameter dish in the case of CD45+ sorted cells, and from 3 to 5 × 106 per dish in the case of unsorted mouse
marrow cells. In all cases, cells were suspended in Myelocult LTC media
(Stem Cell Technologies) with 106 mol/L solucortef
(Sigma-Aldrich Canada, Oakville, Ontario, Canada). Cultures were
maintained at 37°C in 5% CO2 and received weekly 1/2-media changes and twice-weekly additions of SF to give 50 ng/mL. After 5 weeks the entire contents of the culture were harvested by trypsinization and cells placed in methylcellulose assays for detection of AML-CFC as described above.
Limiting dilution analysis in mice.
The frequency of progenitors that initiate AML cell growth in mice was
estimated by limiting dilution analysis. Cohorts of up to 8 mice each
were injected with 5 different doses of AML cells from the same patient
sample, ranging from 1 × 105 to 1 × 107. Because of concerns that the seeding efficiency of the
AML cells would be reduced when very small numbers of cells were
injected, 2 × 106 irradiated (15 Gy) normal human
bone marrow cells were coinjected with leukemic cell doses of 1 × 105 and 3 × 105. Eight weeks after
injection mouse bone marrow was analyzed for percent CD45+
cells, and the frequency of NOD/SCID leukemia-initiating cells (NOD/SL-IC) calculated from the frequency of negative mice in each
group by using Poisson statistics. In cases where the engraftment levels were less than 1% by FACS analysis, DNA analysis was also performed to confirm that small numbers of human cells were not present.
Calculations and statistical analysis.
Comparisons of levels of engraftment and correlation coefficients were
done using a 2-tailed Student t-test. Comparisons between numbers of samples showing high levels of engraftment in mice or
factor-independent colony growth and those expressing growth-factor mRNA were done using  2 analysis. A significance level of
.05 was chosen.
For limiting dilution analysis, the frequency of NOD/SL-IC in the
starting cell population was calculated from the frequency of mice
negative for the presence of AML cells in bone marrow in each group of
animals injected with different numbers of cells as previously
described.29
For calculation of the total number of human AML cells present per
mouse, it was assumed that the number of cells recovered from the
marrow of 4 long bones represented approximately 25% of the entire
mouse bone marrow30 and that more than 90% of the AML
cells in the animal were present in the marrow. The total number of AML
blasts in a mouse at the time of analysis would thus be the percent
CD45+ cells in mouse marrow multiplied by the number of
cells recovered from 4 long bones divided by 0.25.
To determine the average number of cell progeny per NOD/SL-IC, the
calculated number of AML blasts, AML-CFC, or AML-LTC-IC present in the
mouse at week 8 postinjection was divided by the number of NOD/SL-IC
injected into the mouse on day 0 as determined by limiting dilution.
| |
RESULTS |
Variability of engraftment of AML samples in NOD-SCID mice.
Light-density peripheral blood cells were isolated from 61 different
patients with newly diagnosed AML. Eight weeks after IV injections of
107 cells per mouse femoral bone marrow was removed and
analyzed for the presence of human cells by flow cytometry. An average of 3 (range, 1 to 10) mice were analyzed per patient sample and mean
percent CD45+ bone marrow cells in the group of mice
calculated to derive the values shown in
Fig 1. Human CD45+ cells were
easily detectable by flow cytometry in mouse bone marrow for 43 (70%)
of the 61 samples (reliable detection of CD45+ cells above
background fluorescence was 0.5%). Among the 61 samples, the mean ± SEM level of engraftment was 13.3% ± 3.1% (Fig 1A).
View larger version (15K):
[in this window]
[in a new window]
| Fig 1.
Engraftment of AML samples in NOD/SCID mice. The percent
CD45+ cells in mouse marrow was determined for each
sample 8 weeks after IV injection of 107 cells. Each point
represents the mean percent engraftment in the bone marrow of all mice
injected with cells from an individual patient sample (mean, 3 mice per
sample; range, 1 to 10 mice). The numerical values shown are the means
for each group of samples. (A) Influence of cytogenetic abnormalities.
Changes associated with a poor prognosis included inv(3), +8, 11q23
rearrangements, t(9;22), del(20q), del(7q), +13, t(12;22), and a
variety of complex abnormalities. Changes associated with a good
prognosis included inv(16) or variants, or t(15;17). There was a trend
toward higher levels of engraftment with samples with poor-risk
cytogenetic features (P = .06). (B) Influence of FAB subtype.
Fifty-seven of the 61 samples could be classified into AML subtypes
according to FAB criteria. The mean engraftment levels obtained from
each subtype are shown. Levels of engraftment were lower with samples
with FAB subtypes M3 (P = .002) and M2 (P = .06)
than with other subtypes. ( ), AML samples with cytogenetic
abnormalities with a poor prognosis; ( ), samples with cytogenetic
change with favorable prognosis; ( ), samples with normal
cytogenetics and intermediate prognosis.
|
|
Thirty-two of the 61 patient samples (52%) had cytogenetic
abnormalities detected in their diagnostic bone marrow samples. Thirteen samples had cytogenetic changes associated with a good clinical prognosis, ie, inv(16) or variants (n = 11) or t(15;17) (n = 2).31 The mean level of engraftment in this group was 5.7% (range, <0.1% to 35%). The remaining 19 samples had chromosomal rearrangements associated with a poor prognosis. These abnormalities included inv(3), +8, 11q23 rearrangements, t(9;22), del(20q), del(7q),
+13, t(12;22), and a variety of complex abnormalities. The mean level
of engraftment in mouse bone marrow in this group was 20.5% (range,
<0.1% to 100%). As shown in Fig 1A, it appears that AML samples
with poor-risk cytogenetic features often engraft in mice to higher
levels than those with changes associated with a good prognosis.
However, there is considerable heterogeneity and overlap between the 2 groups and the difference in levels of engraftment obtained did not
reach statistical significance (P = .06 by Student
t-test).
Fifty-seven of the group of 61 AML samples could be classified into
different AML subtypes according to FAB criteria.18 When
the levels of engraftment of these different cell types in mice were
compared among the subgroups, the lowest mean percent human cells in
mouse marrow was seen among the AML M0 (n = 1), M2 (n = 4), and M3 (n = 5) samples (0.24%, 4.5%, and 1.8%, respectively), whereas the
highest were seen among those with M1 (n = 8), M4 (n = 24), and M5 (n = 11) subtypes, 13.7%, 14.6%, and 18.9%, respectively. The difference
in levels of engraftment between M3 samples and all others was highly
statistically significant (P = .002) and approached
significance (P = .06) for M2 samples (Fig 1B). Figure 1B also
indicates the cytogenetic prognostic subgroup for the patient samples
in the different FAB subtypes where cytogenetic abnormalities had been
detected. Among patients with FAB subtypes M2 and M5, all those with
detectable cytogenetic abnormalities had chromosome rearrangements
associated with a poor prognosis. In contrast, the 2 M3 samples that
were cytogenetically abnormal both had the favorable prognostic change
t(15;17). Two samples with unfavorable and 1 with favorable prognostic
abnormalities were found among the 9 AML-M1 cases. The most
heterogeneity was seen among the M4 AMLs. As expected, all but 1 of the
11 patient samples with good prognosis chromosome 16 abnormalities were
found in this group. However, an additional 8 patients with changes associated with a poor prognosis were also classified with this FAB subtype.
To confirm that the human cells growing in the mice were leukemic,
May-Grünwald-Giemsa-stained bone marrow touch preparations or
cytospins of marrow cells from mice 8 weeks posttransplant were
examined for 21 patient samples. The proportion of blast cells
identified in the differential cell counts on these slides were in most
cases comparable to the percent CD45+ cells as assessed by
flow cytometry (r = .74, P < .001). In some cases,
characteristic morphological features such as dysplastic eosinophils
from AML M4eo samples were clearly distinguishable in mouse marrow
samples (Fig 2A).
View larger version (78K):
[in this window]
[in a new window]
| Fig 2.
(A) Bone marrow smear from a mouse 8 weeks after
injection with cells from a patient with AML M4Eo showing the
characteristic morphology of this subtype, including dysplastic
eosinophils (black arrowhead) and leukemic blasts (white arrowheads).
(B) FISH on a colony grown from the marrow of a mouse 8 weeks after
injection with cells from pt 8. The probe used was D8Z2, which is
specific for centromeric repeat sequences on human chromosome 8. The
+8 abnormality previously identified in the leukemic clone of this
patient is illustrated.
|
|
Four AML samples that engrafted well in mice had cytogenetic markers
that could be detected easily by FISH on interphase cells. Three
samples with the +8 abnormality (pts 6, 7, and 8) showed levels of
engraftment of CD45+ cells at week 8 postinjection of 5%,
3%, and 15%. FACS-sorted CD45+ cells from these mice
showed the +8 abnormality in 95%, 15%, and 100% of analyzed cells,
respectively (Fig 2B). For a fourth sample (pt 5), in which 37% of
metaphases in the patient's diagnostic bone marrow contained trisomy
13, 50% of mouse marrow cells were CD45+ at week 8 and
27% of these were +13 by FISH. Thus, the human cells engrafting in
these animals are characteristic of the malignant clone initially
identified in patients both morphologically and cytogenetically.
The spleen and peripheral blood of animals injected with 59 of the AML
samples were also examined for the presence of human leukemic cells.
Although in every case the proportion of human cells detected was lower
in spleen and blood than in the marrow (mean percent human cells,
2.7%, 3.0% and 12.0%, respectively) there was a direct correlation
between the percent AML cells in each of these tissues (r = .63, .76, and .85 for comparison of percent human cells in marrow and
spleen, marrow and blood, and spleen and blood, respectively; P < .001, Student t-test). All of the 16 patient samples where
the proportion of human cells in marrow was greater than 10% had AML
cells easily detected in spleen and 15 also had human leukemic cells
detected in blood.
Treatment of mice with human cytokines does not improve the overall
ability of AML samples to engraft NOD-SCID mice.
The original description of growth of human AML cells in
immunodeficient (SCID) mice had suggested that repeated injections of
human cytokines were necessary to achieve high levels of engraftment. Although this suggestion is consistent with the known
cytokine-responsiveness of human AML cells in vitro, in the current
study we discovered that 13 of the 61 samples showed  25% human
leukemic cells in mouse marrow 8 weeks postinjection without treatment
of the mice with any human growth factors. Nevertheless, because we
were unable to show engraftment of all samples tested and the level of
engraftment of human cells was low in a number of others, we studied
the ability of cytokine injections to enhance the levels of human AML
cells detected in NOD/SCID mice. Because greater than 90% of AML blast samples will proliferate in response to the combination of IL-3 and SF
as measured in short-term 3H-thymidine incorporation
assays,2 we chose to test these growth factors for their
effect on AML cell growth in mice. 107 cells per mouse from
different AML samples were injected into groups of 4 mice each. Four
weeks after injection of AML cells, 1 animal in each cohort was killed.
For 36 AML samples, the bone marrow of this mouse contained less than
25% CD45+ cells. After this had been determined, 1 of the
3 remaining mice in these cohorts began to receive 6 µg of human IL-3
and 10 µg of human SF intraperitoneally Monday, Wednesday, and
Friday, while the second mouse received IL-3 only according to the same
dose and schedule, and the third mouse continued to not receive any cytokines. Cytokine levels in the serum of a treated mouse 1.5 hours
postinjection were 8,000 pg/mL of IL-3 and greater than 100,000 pg/mL
of SF, while levels at 48 hours postinjection and immediately before
the next scheduled dose of cytokine(s) had decreased to undetectable
levels for IL-3 and 55 pg/mL of SF. When these groups of 3 mice were
analyzed at week 8 after initial injection of AML cells, the mean ± SEM proportions of human cells in mouse bone marrow were not
significantly different for animals receiving or not receiving human
cytokines (2.6% ± 1.0% for animals that never received cytokines
[n = 36], 3.5% ± 1.7% for animals treated with IL-3 only [n = 19], and 2.6% ± 0.9% for animals treated with IL-3 and SF [n = 36]).
Although these results suggested that cytokines of the type and dose
injected were ineffective in enhancing AML cell growth in mice, there
were 4 samples in which comparison of the individual cytokine-treated
and untreated mice suggested a possible enhancement of engraftment with
the combination of IL-3 and SF. Thus, the above experiment was repeated
with these cells with larger numbers of mice in the treated and
untreated groups. Table 2 shows the results
from these 4 experiments. In no case was the difference between mice
treated or not treated with cytokines statistically significant.
Factor-independent growth of AML-CFC predicts AML cell growth in
mice.
A subset of AML cells from most patient samples will form colonies of
blast cells when placed in semisolid medium with a source of
cytokines.1 However, the growth of these AML-CFC from some patient samples appears to be relatively
factor-independent.2,32,33 When 45 of the AML samples that
were tested in mice were placed in methylcellulose assay containing
serum but no other source of cytokines, 17 developed 5 colonies per
105 cultured cells. One additional patient showed less than
5 colonies but equivalent numbers of small clusters both with and
without cytokines. These 18 samples were considered to show
factor-independent AML-CFC growth. In 25 cases  1 colony formed per
105 cells without growth factors, but when cytokines were
added to cultures, colonies formed in every case. In the remaining 2 cases, 2 or 3 colonies per 105 cells formed without
cytokines but there was a greater than 10-fold increase in colony
numbers when cytokines were added. The latter 27 cases were considered
to be factor dependent. When the ability of AML samples that were
either factor dependent or independent in colony assays were compared
for their ability to grow in mice, there was a significant difference
(P = .03) with factor-independent samples showing higher
proportions of human cells in mouse bone marrow than factor-dependent
samples (Fig 3).
View larger version (10K):
[in this window]
[in a new window]
| Fig 3.
AML-CFC factor independence is associated with increased
growth of AML cells in mice. Engraftment levels obtained from samples
which could be classified as either growth-factor dependent or
independent in methylcellulose colony assays are compared. Samples that
were factor independent showed a significantly higher mean level of
engraftment than those which were factor dependent (P = .03).
|
|
Growth-factor mRNA expression in AML blasts predicts high-level
engraftment in mice.
To assess the possibility that autocrine growth-factor production might
be associated with differences in the growth of human leukemic cells in
mice, reverse transcriptase (RT)-PCR was used to generate total cDNA
from 19 AML samples where levels of engraftment in NOD/SCID mice had
previously been determined. If hybridization of Southern blots of the
total cDNA with probes specific for the 4 candidate cytokines failed to
show evidence of expression of these genes, a second round of PCR using
primers specific for the human growth factors SF, IL-3, GM-CSF, and
G-CSF was performed as described in Materials and Methods. IL-3
expression was detected in 4 AML samples, SF expression in 6, and G-CSF
expression in 2. In 3 of these samples both IL-3 and SF expression was
detected. When leukemic blasts from patient 8 in Table 1 which showed
factor-independent colony growth were sorted into subpopulations based
on their expression of CD34 and CD38, 80% of the cells in each
fraction was cytogenetically abnormal by FISH.21 IL-3
expression was detected in all 3 of the subpopulations:
CD34+CD38,
CD34+CD38+, and CD34 on
Southern blotting of total cDNA (Fig 4A).
Among the 19 samples tested for growth-factor gene expression, 9 showed
greater than 10% human AML cells in mouse marrow 8 weeks after
injection of 107 leukemic blasts. Seven of these 9 had cDNA
detected for 1 or more of the 4 cytokines evaluated. In constrast, only
2 of the remaining 10 samples that engrafted to levels of less than
10% under the same conditions had detectable cytokine message (Fig 4).
The difference in proportion of samples with detectable cytokine expression between those with greater than or less than 10%
engraftment in NOD/SCID marrow was significant by 2
analysis (P < .02). Six of the 9 samples in which cytokine
expression was detected produced factor-independent AML-CFC growth,
while 3 of 10 cytokine-negative samples were factor independent in this assay (P < .1).
View larger version (44K):
[in this window]
[in a new window]
| Fig 4.
Growth-factor mRNA expression in AML blasts. RT-PCR was
used to generate total cDNA from AML samples. (A) Southern blots of
total cDNA from the CD34+CD38,
CD34+CD38+, and CD34
fractions of cells from pt 8 in Table 1 hybridized with probes specific
for IL-3, SF, G-CSF, GM-CSF and, as a positive control, -actin. IL-3
expression was detected in all 3 subpopulations. SF, G-CSF, and GM-CSF
expression was undetectable. RT, reverse transcriptase. (B) Total cDNA
from 15 AML samples was subjected to a second round of PCR using
cytokine specific primers. Patients A through H showed less than 10%
human AML cells in mouse marrow 8 weeks after injection of
107 cells; patients I through O showed greater than 10%
human AML cells in mouse marrow under the same conditions. For each
cytokine, the positive control was a murine cell line transfected with
the corresponding human cytokine cDNA. Southern blots of PCR products
were hybridized with the corresponding cytokine-specific probes.
Expression of 1 or more cytokines was detected in 2 of the 8 samples
shown that achieved less than 10% engraftment, and in 5 of the 7 samples shown that achieved greater than 10% engraftment. In a
separate experiment, 2 additional samples with less than 10%
engraftment showed no detectable growth-factor expression while 1 sample with greater than 10% engraftment showed expression of G-CSF
message.
|
|
Kinetics of engraftment.
The kinetics with which human leukemic cells engraft and proliferate in
NOD/SCID mice were examined in 3 experiments, each performed with a
different patient sample. Animals injected with 1 × 107 cells were killed at various times postinjection, the
marrow from 4 long bones analyzed for CD45+ cells, and the
calculated total number of human cells present in the mice plotted over
time as shown in Fig 5. Human cells were detectable in 10- to 100-fold lower numbers than the number initially injected 2 days postinjection. Thereafter, a rapid expansion of CD45+ cell numbers was seen in the bone marrow which
continued throughout the 8-week period of assessment. The fold-increase
in human cells between 2 days and 8 weeks postinjection ranged from 20- to almost 5,000-fold. These data suggested that a relatively small
number of cells in the initial inoculum was responsible for the growth and maintenance of leukemic cells in the animals.
View larger version (15K):
[in this window]
[in a new window]
| Fig 5.
Kinetics of AML cell growth in NOD/SCID mice. Animals
injected with 107 cells from pts 6, 8, and 11 were killed
at various timepoints postinjection and the total number of
CD45+ cells per mouse was determined by FACS and plotted
over time. A continuous expansion in cell numbers throughout the
8-week-period of assessment was seen.
|
|
Limiting dilution analysis of AML progenitors engrafting in NOD/SCID
mice.
In previous studies we have used limiting dilution analysis to show
that the frequency of AML progenitors that initiate long-term culture
(AML LTC-IC) is 10- to greater than 100-fold lower than the frequency
of AML-CFC in the same patient sample, and that each LTC-IC will
generate more than 1 clonogenic cell progeny over 5 weeks in
culture.2 Using the same principles, we determined the
frequency of cells capable of initiating growth of leukemic cells in
NOD/SCID mice (NOD/SCID leukemia-initiating cells or NOD/SL-IC). Five
different doses of the same AML sample ranging from 1 × 105 to 1 × 107 cells were injected into
cohorts of up to 8 mice each. Using Poisson statistics, the frequency
of NOD/SL-IC in a given sample was calculated based on the frequency of
mice in which CD45+ cells could not be detected in bone
marrow 8 weeks after injection of each cell dose. Because the limit of
sensitivity of FACS analysis for CD45+ cells was 0.5%,
apparently negative FACS results were confirmed by hybridizing Southern
blots of genomic DNA from mouse tissues with a human-specific probe for
endogenous retroviral sequences (HERV-H). As described in Materials and
Methods, this technique allows detection of less than 0.1% human cells
in mouse tissues. The results of limiting dilution experiments with 6 AML samples (pts 5 through 10) are shown in
Table 3. The frequencies of NOD/SL-IC ranged from 0.7 to 45 per 107 cells. This number was 214- to 800-fold lower than the frequency of LTC-IC determined previously
for 3 of the same 6 patient samples.2
After determining the frequency of NOD/SL-IC in these samples, it was
possible to use these values to quantitate the numbers of cell progeny
of different types produced per NOD/SL-IC. The average number of AML
blast cell progeny produced by each NOD/SL-IC at week 8 postinjection
ranged from 1.1 × 106 to 7.5 × 106
cells/NOD/SL-IC (mean ± SEM, 3.7 × 106 ± 1.0 × 106) (Table 4).
Assays for AML-CFC were performed on bone marrow cells from mice
engrafted with cells from pts 6 and 8. The number of CFC produced at
week 8 postinjection per NOD/SL-IC was 497 and 4,877 for cells from pts
6 and 8, respectively. FISH analysis of cells from colonies grown from
such samples showed that 100% of AML-CFC carried the +8 abnormality
characteristic of the leukemic clone (Fig 2B, Table 4). These same
samples were also analyzed for the presence of AML-LTC-IC. For samples
from pts 6 and 8 the average numbers of LTC-IC produced per NOD/SL-IC
was 599 and 36, respectively, with FISH analysis confirming the
presence of the +8 abnormality in AML LTC-IC from patient 8 (Table 4).
Secondary transplants of NOD/SL-IC.
To determine if AML progenitors capable of engrafting in mice persisted
for significant time periods posttransplantation and to quantitate
their numbers, NOD/SCID animals injected with AML cells 3 to 4 weeks
previously were killed and their bone marrow cells transplanted into
secondary recipients. When bone marrow from the secondary recipients
was analyzed 8 to 12 weeks later, 2 of 3 mice injected with cells from
primary recipients of AML cells from patients 5 and 10 and 1 of 3 mice
injected with marrow from a recipient of patient 9 cells showed
engraftment with human cells (Table 5).
Using Poisson statistics, it can be estimated from this data that the
marrow of the primary mice contained approximately 10 to 20 NOD/SL-IC
at the time of secondary transfer. Because the primary mice were
injected with AML cells from 3 samples for which the frequency of
NOD/SL-IC had previously been determined at limiting dilution (Table
3), it was possible to compare the number of NOD/SL-IC injected into
primary mice initially with the number recovered 3 to 4 weeks later. As
shown in Table 5, at least in the case of cells from patients 5 and 9, the number of NOD/SL-IC was apparently well preserved over that time
period. Furthermore, FISH performed on CFC grown from the bone marrow of a secondary recipient of cells from patient 5 harvested 12 weeks
posttransplant carried the +13 cytogenetic abnormality characteristic of the leukemic clone in 8 of 9 colonies, confirming the malignant nature of these progenitors.
| |
DISCUSSION |
Over the last few years, evidence has been accumulating to support the
hypothesis that malignant transformation in AML typically occurs in a
rare primitive hematopoietic progenitor with many of the
characteristics associated with normal multipotential hematopoietic precursors or `stem cells.' These characteristics include the ability
to initiate long-term hematopoiesis in culture,2 the expression of cell-surface antigens such as CD34,17 and the relative lack of expression of molecules such as CD38, CD71, and HLA-DR
that are expressed by more mature, lineage-committed
progenitors,15,16 and the ability to engraft and
proliferate in the marrow of immunodeficient mice.15-17 The
availability of an in vivo assay for cells responsible for maintenance
of the malignant clone has obvious importance for the development of
new therapeutic strategies and for more basic studies aimed at a
further understanding of leukemic stem cell biology.
The first description of an in vivo assay for human AML progenitors in
immunodeficient mice used sublethally irradiated SCID animals injected
with human cytokines.14 Although this assay for SL-IC was a
clear demonstration of the feasibility of this approach, the somewhat
low and inconsistent levels of engraftment obtained limited the
usefulness of the technique. We and others have found that the use of
NOD/SCID mice as hosts for leukemic progenitors directly isolated from
AML patients has greatly enhanced the sensitivity and reproducibility
of the NOD/SL-IC assay over that which can be obtained with SCID mice
and a variety of other immunodeficient strains (data not
shown).15 As shown by the data presented here, 8 weeks
after IV injection of 107 light-density peripheral blood
cells from patients with newly diagnosed AML, human CD45+
cells were usually easily detected in NOD/SCID mouse bone marrow. The
leukemic origin of these cells was obvious from their characteristic morphology and could be confirmed by demonstration of chromosomal abnormalities that had previously been identified in the patient's diagnostic bone marrow cytogenetic analysis. Thus, the use of these
animals allows the routine detection and quantitation of primitive
leukemic progenitors from most patient samples.
In preliminary experiments, we observed that the proportion of human
cells detected in mouse marrow increased with the number of AML cells
initially injected (data not shown). Thus, to compare the ability of
various patient samples to grow in mice, a standardized cell dose was
selected. The dose of 107 cells was chosen because of
limitations in cell numbers from some samples and because this number
of cells appeared to be adequate to generate reproducible engraftment
from many samples. However, as indicated in Table 3, the frequency of
NOD/SL-IC in some patient samples is less than 1 in 107
cells. Thus, the low or undetectable numbers of human cells observed in
some cases may reflect the injection of inadequate cell numbers. The
8-week endpoint for most of these experiments was chosen after initial
studies had indicated that the level of engraftment continued to
increase steadily until that timepoint and to provide a standard endpoint for comparison of the growth characteristics in different samples. However, it is likely that choice of a different timepoint would have yielded somewhat different overall results. In a limited number of experiments it was possible to show continued expansion of
AML cell numbers up to 12 to 14 weeks postinjection into mice. Unfortunately, because of the inherent tendency of NOD/SCID mice to
spontaneously develop malignant thymomas as they age, it is difficult
to continue these experiments much beyond that timepoint.6
Since the original description of the ability of AML cells to form
colonies in semisolid media, it has been recognized that AML
progenitors share at least some of the cytokine-responsiveness of their
normal cell counterparts.1 Although some cytokines that
stimulate normal and malignant myelopoiesis show species cross-reactivity between mice and humans, a number of key molecules, such as IL-3, do not, and others, such as SF, show less potency on
cells from a different species of origin.34,35 Thus, it seemed reasonable to suppose that provision of relevant human growth
factors would enhance the growth of human AML cells in mice. However,
it has also been well-documented that progenitors in many AML samples
can exhibit varying degrees of factor-independent growth. In many
cases, this is associated with autocrine growth-factor production.36-39 Thus, it was not certain whether human
cytokines would be necessary to allow the growth of all leukemic
samples in mice. In fact, using the protocol established in this study, 17 of the 61 samples tested showed more than 10% replacement of NOD/SCID marrow with leukemic cells in the absence of any human cytokine supplements. In comparing the growth-factor requirements for
45 of these 61 AML samples in colony assays with their ability to grow
in mice, we discovered that most (9 of 14) samples which showed more
than 10% replacement of mouse marrow with AML cells demonstrated
factor-independent growth in AML-CFC assays. To explore the possibility
that autocrine growth-factor production might be associated with more
rapid growth of human AML cells in NOD/SCID mice, RT-PCR was used to
amplify mRNA for 4 candidate growth factors from AML blasts. The 4 factors (SF, IL-3, G-CSF, and GM-CSF) were chosen because more than
90% of AML samples will respond to 1 or more of these factors alone or
in combination in in vitro assays. In addition, these cytokines had all
been shown to be produced in an autocrine fashion by some leukemia
samples in previous studies.32,38,40-42 However, AML blasts
may produce a variety of other growth factors and their
receptors.33 Thus, the data shown in Fig 4 represent a
minimal estimate of the autocrine factor production in these cells.
Nevertheless, consistent with previous data, we found that most samples
expressing 1 or more of the 4 growth factors studied exhibited
factor-independent growth in AML-CFC assays.32,33 Even more
striking was the association between growth factor gene expression and
high-level engraftment of AML cells in NOD/SCID mice.
In this study we chose to inject IL-3 and SF thrice weekly
intraperitoneally into mice for 4 weeks before killing of the animals for analysis. In previous experiments testing a variety of growth factors alone and in combination, we had found that this combination stimulated maximal proliferation of AML blasts in short-term assays and
that AML LTC-IC also responded to these cytokines.2
Initiation of cytokine injections was delayed until 4 weeks
postinjection of AML cells to allow detection of factor-independent AML
cell growth in an initial test animal and thereby avoid cytokine
injections if they were unnecessary. In addition, human growth factor
injections for 2 weeks before killing of NOD/SCID mice previously
injected with adult human bone marrow cells had been shown to enhance
detection of normal myeloid progenitors.11 Although the
dose of both factors administered was high enough to achieve
substantial serum levels immediately postinjection, their relatively
short half-life resulted in little or no detectable cytokine by the
time of the next injection. Thus, although it is clear that the dose
and schedule of cytokine administration chosen did not improve the
growth of human AML cells in NOD/SCID mice, beginning the injections
earlier or giving them more frequently or at higher dosages may have
produced different results. Other investigators have suggested that
there is a relationship between the dose of hIL-3 administered and the
level of AML cell engraftment observed in SCID mice.43 The
fact that leukemic cells which showed cytokine-dependent colony growth
and lacked detectable growth-factor mRNA expression often failed to
grow well in mice also suggests that an alternative strategy for human growth-factor administration may be necessary to optimize the sensitivity of the NOD/SL-IC assay. We are particularly interested in
the possibility that immunodeficient mice transgenic for human cytokine
genes may provide improved hosts for human AML
progenitors.44,45 In addition, newly developed mouse
strains with more profound immunodeficiency than the NOD/SCID animals
may enhance engraftment with both normal and malignant human
hematopoietic cells.46
The proportion of leukemic cells detected in mouse marrow after
injection of AML samples known to contain chromosomal rearrangements associated with a good clinical prognosis was generally lower than that
observed after injection of cells with rearrangements associated with a
poor prognosis (Fig 1A). Similarly, as shown in Fig 1B, the levels of
engraftment were higher with samples from patients with AML FAB
subtypes M1, M4, and M5 than with AML-M3 and M2 samples. Clinically,
AML-M3 has a relatively favorable prognosis compared with AML-M5, which
is associated with an aggressive course and poor overall
survival.47,48 In NOD/SCID mice, human leukemic cells will
also disseminate from bone marrow into both the peripheral blood and
spleen, and this occurs as bone marrow infiltration becomes more
extensive. Although most of the animals in this study were killed
before advanced tumor growth could cause their death, in some cases
unexpected deaths were associated with extensive infiltration of AML
cells in marrow and other hematopoietic tissues. Thus, the development
and spread of leukemia in NOD/SCID mice resembles in many ways the
clinical disease in patients.
NOD/SL-IC are rare progenitors, as shown at limiting dilution on Table
3. These frequencies are consistent with those reported by others using
similar techniques and are not greatly different from the frequencies
determined for NOD/SCID competitive repopulating units (CRU) in normal
human bone marrow.11 These frequencies are, however,
several hundred-fold lower than the frequencies previously determined
for AML LTC-IC detected in 5-week-old cultures.2 These
relative frequencies are similar to those previously determined for
normal CRU and LTC-IC.10,49,50 The proliferative capacity of NOD/SL-IC is high. Each of these progenitors is capable of producing
more than 106 leukemic blasts and hundreds of AML-CFC
(Table 4). In 2 cases it was possible to show that AML LTC-IC were also
produced in large numbers. These data contrast with the average cell
production for AML LTC-IC, which for cells from patients 6 and 8 had
been previously determined as 1.8 and 1.2 AML-CFC per LTC-IC,
respectively.2 One interpretation of these differences in
frequency and proliferative capacity is that they indicate that the
NOD/SL-IC and AML LTC-IC assays detect different populations of
progenitor cells. Studies of retroviral-mediated gene transfer
efficiencies and cell-surface phenotype have suggested to some
investigators that this may be the case for normal LTC-IC and
progenitors that are detected in NOD/SCID mice.51 However,
using similar comparisons, others have obtained data consistent with a
close relationship between these 2 cell types.49,52 Recent
studies of our own have also shown that the majority of AML progenitors
that initiate long-term malignant hematopoiesis in culture share the
cell-surface phenotype of NOD/SL-IC and are predominantly
CD71 and HLA-DR as well as
CD38 and CD34+.16,21 Thus,
it appears likely that the LTC-IC and NOD/SL-IC assays detect
overlapping, if not identical, populations of progenitors. The apparent
differences in the frequency and proliferative capacity of the cells
detected is likely to be at least partly explained by differences in
the sensitivity of the 2 assays and their relative ability to support
the proliferative potential of the cells detected.
Under the conditions used in these experiments, NOD/SL-IC numbers are
maintained at relatively constant levels for at least 3 to 4 weeks
posttransplantation into mice (Table 5) while other investigators have
suggested that an absolute expansion of their numbers may be possible
in vivo.15 This apparent ability to self-renew their own
numbers combined with the potential to differentiate to produce large
numbers of more committed progenitors and mature leukemic blasts
suggests NOD/SL-IC as candidate leukemic `stem cells.' These
primitive characteristics and the ability to sensitively detect and
quantitate NOD/SL-IC from the majority of AML samples suggests the use
of this assay for preclinical evaluation of novel therapeutic
strategies53 and to study the relative importance of
specific molecular abnormalities in the in vivo behavior of the
leukemic clone.
| |
FOOTNOTES |
Submitted August 27, 1998; accepted May 4, 1999.
Supported by grants from the National Cancer Institute of Canada with
funds from the Terry Fox Foundation and the B.C. Health Research
Foundation. L.E.A. was the recipient of a Roman N. Babicki Fellowship
in Medical Research.
The publication costs of this
article were defrayed in part by
page charge payment. This article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
Address reprint requests to Donna E. Hogge, MD, PhD, Terry Fox
Laboratory, B.C. Cancer Agency, 601 W 10 Ave, Vancouver, BC Canada V5Z
1L3; e-mail: donna{at}terryfox.ubc.ca.
| |
REFERENCES |
1.
Buick RN, Till JE, McCulloch EA:
Colony assay for proliferative blast cells circulating in myeloblastic leukemia.
Lancet
1:862, 1977[Medline]
[Order article via Infotrieve]
2.
Ailles LE, Gerhard B, Hogge DE:
Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines.
Blood
90:2555, 1997[Abstract/Free Full Text]
3.
Sutherland HJ, Blair A, Zapf RW:
Characterization of a hierarchy in human acute myeloid leukemia progenitor cells.
Blood
87:4754, 1996[Abstract/Free Full Text]
4.
Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge DE:
Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells.
Blood
78:666, 1991[Abstract/Free Full Text]
5.
Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, Largman C, Lawrence HJ, Humphries RK:
Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells.
Proc Natl Acad Sci USA
91:12223, 1994[Abstract/Free Full Text]
6.
Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH:
Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.
J Immunol
154:180, 1995[Abstract]
7.
Pflumio F, Izac B, Katz A, Shultz LD, Vainchenker W, Coulombel L:
Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells.
Blood
88:3731, 1996[Abstract/Free Full Text]
8.
Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE:
Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.
Proc Natl Acad Sci USA
94:5320, 1997[Abstract/Free Full Text]
9.
Cashman J, Bockhold K, Hogge DE, Eaves AC, Eaves CJ:
Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haematopoietic cells in NOD/SCID mice transplanted with human cord blood.
Br J Haematol
98:1026, 1997[Medline]
[Order article via Infotrieve]
10.
Wang JCY, Doedens M, Dick JE:
Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay.
Blood
89:3919, 1997[Abstract/Free Full Text]
11.
Cashman JD, Lapidot T, Wang JCY, Doedens M, Shultz LD, Lansdorp P, Dick JE, Eaves CJ:
Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice.
Blood
89:4307, 1997[Abstract/Free Full Text]
12.
Sirard C, Lapidot T, Vormoor J, Cashman JD, Doedens M, Murdoch B, Jamal N, Messner H, Addey L, Minden M, Laraya P, Keating A, Eaves A, Lansdorp PM, Eaves CJ, Dick JE:
Normal and leukemic SCID-repopulating cells (SRC) co-exist in the bone marrow and peripheral blood from CML patients in chronic phase while leukemic SRC are detected in blast crisis.
Blood
87:1539, 1996[Abstract/Free Full Text]
13.
Wang JCY, Lapidot T, Cashman JD, Doedens M, Addy L, Sutherland DR, Nayar R, Laraya P, Minden M, Keating A, Eaves AC, Eaves CJ, Dick JE:
High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase.
Blood
91:2406, 1998[Abstract/Free Full Text]
14.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE:
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
Nature
367:645, 1994[Medline]
[Order article via Infotrieve]
15.
Bonnet D, Dick JE:
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.
Nat Med
3:730, 1997[Medline]
[Order article via Infotrieve]
16.
Blair A, Hogge DE, Sutherland HJ:
Most acute myeloid leukaemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71/HLA-DR.
Blood
92:4325, 1998[Abstract/Free Full Text]
17.
Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ:
Lack of expression of Thy-1 (CD90) on acute myeloid leukaemia cells with long-term proliferative ability in vitro and in vivo.
Blood
89:3104, 1997[Abstract/Free Full Text]
18.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C:
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.
Ann Intern Med
103:620, 1985
19.
Sambrook J, Fritsch EF, Maniatis T:
Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989.
20.
Mager DL, Freeman JD:
Human endogenous retroviruslike genome with type C pol sequences and gag sequences related to human T-cell lymphotropic viruses.
J Virol
61:4060, 1987[Abstract/Free Full Text]
21.
Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE:
Expression of Hox genes, Hox-cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.
Leukemia
13:687, 1999[Medline]
[Order article via Infotrieve]
22.
Cleveland DW, Lopata MA, MacDonald RJ, Cowan NJ, Rutter WJ, Kirschner MW:
Number and evolutionary conservation of - and -tubulin and cytoplasmic - and  -actin genes using specific cloned cDNA probes.
Cell
20:95, 1980[Medline]
[Order article via Infotrieve]
23.
Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA, Birkett NC, Smith KA, Johnson MJ, Parker VP, Flores JC, Patel AC, Fisher EF, Erjavec HO, Herrera CJ, Wypych J, Sachdev RK, Pope JA, Leslie I, Wen D, Lin CH, Cupples RL, Zsebo KM:
Primary structure and functional expression of rat and human stem cell factor DNAs.
Cell
63:203, 1990[Medline]
[Order article via Infotrieve]
24.
Yang YC, Ciarletta AB, Temple PA, Chung MP, Kovacic S, Witek-Giannotti JS, Leary AC, Kriz R, Donahue RE, Wong GG, Clark SC:
Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3.
Cell
47:3, 1986[Medline]
[Order article via Infotrieve]
25.
Cantrell MA, Anderson D, Cerreti DP, Price V, McKereghan K, Tushinski RJ, Mochizuki DY, Larsen A, Grabstein K, Gillis S, Cosman D:
Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor.
Proc Natl Acad Sci USA
82:6250, 1985[Abstract/Free Full Text]
26.
Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H, Ono M:
Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.
Nature
319:415, 1986[Medline]
[Order article via Infotrieve]
27.
Langston AW, Gudas LJ:
Retinoic acid and homeobox gene regulation.
Curr Opin Genet Dev
4:550, 1994[Medline]
[Order article via Infotrieve]
28.
Sutherland HJ, Hogge DE, Cook D, Eaves CJ:
Alternative mechanisms with and without Steel factor support primitive human hematopoiesis.
Blood
81:1465, 1993[Abstract/Free Full Text]
29.
Szilvassy SJ, Humphries RK, Lansdorp PM, Eaves AC, Eaves CJ:
Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy.
Proc Natl Acad Sci USA
87:8736, 1990[Abstract/Free Full Text]
30.
Boggs DR:
The total marrow mass of the mouse: a simplified method of measurement.
Am J Hematol
16:277, 1984[Medline]
[Order article via Infotrieve]
31.
Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD:
Clinical significance of cytogenetics in acute myeloid leukemia.
Semin Oncol
24:17, 1997[Medline]
[Order article via Infotrieve]
32.
Young DC, Demetri GD, Ernst TJ, Cannistra SA, Griffin JD:
In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.
Exp Hematol
16:378, 1988[Medline]
[Order article via Infotrieve]
33.
Lowenberg B, Touw IP:
Hematopoietic growth factors and their receptors in acute leukemia.
Blood
81:281, 1993[Free Full Text]
34.
Morstyn G, Burgess AW:
Hemopoietic growth factors: A review.
Cancer Res
48:5624, 1988[Abstract/Free Full Text]
35.
Broxmeyer HE, Cooper S, Lu L, Hangoc G, Anderson D, Cosman D, Lyman SD, Williams DE:
Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells.
Blood
77:2142, 1991[Abstract/Free Full Text]
36.
Oster W, Lindemann A, Mertelsmann R, Herrmann F:
Regulation of gene expression of M-, G-, GM-, and multi-CSF in normal and malignant hematopoietic cells.
Blood Cells
14:443, 1988[Medline]
[Order article via Infotrieve]
37.
Rogers SY, Bradbury D, Kozlowski R, Russell NH:
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells.
Exp Hematol
22:593, 1994[Medline]
[Order article via Infotrieve]
38.
Young DC, Wagner K, Griffin JD:
Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia.
J Clin Invest
79:100, 1987
39.
Oster W, Cicco NA, Klein H, Hirano T, Kishimoto T, Lindemann A, Mertelsmann RH, Hermann F:
Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia.
J Clin Invest
84:451, 1989
40.
Cheng GYM, Kelleher CA, Miyauchi J, Wang C, Wong G, Clark SC, McCulloch EA, Minden MD:
Structure and expression of genes of GM-CSF and G-CSF in blast cells from patients with acute myeloblastic leukemia.
Blood
71:204, 1988[Abstract/Free Full Text]
41.
Meeker TC, Hardy D, Willman C, Hogan T, Abrams J:
Activation of the interleukin-3 gene by chromosome translocation in acute lymphoblastic leukemia with eosinophilia.
Blood
76:285, 1990[Abstract/Free Full Text]
42.
Caceres-Cortes JR, Hoang T:
Product of the Steel locus can replace leukemic cell interaction.
Cancer Res
52:5208, 1992[Abstract/Free Full Text]
43.
Terpstra W, Prins A, Visser T, Wognum B, Wagemaker G, Lowenberg B, Wielenga J:
Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice.
Leukemia
9:1573, 1995[Medline]
[Order article via Infotrieve]
44.
Bock TA, Orlic D, Dunbar CE, Broxmeyer HE, Bodine DM:
Improved engraftment of human hematopoietic cells in severe combined immunodeficient (SCID) mice carrying human cytokine transgenes.
J Exp Med
182:2037, 1995[Abstract/Free Full Text]
45.
Nicolini FE, Cashman JD, Humphries RK, Eaves CJ:
Continuous exposure of human stem cells in NOD/SCID mice to human IL-3, GM-CSF and Steel factor (SF) alters the number and types of primitive and mature cells they produce.
Blood
92:718a, 1998 (abstr, suppl 1)
46.
Christianson SW, Greiner DL, Hesselton R, Leif JH, Wagar EJ, Schweitzer IB, Rajan TV, Gott B, Roopenian DC, Shultz LD:
Enhanced human CD4+ T cell engraftment in b2-microglobulin-deficient NOD-scid mice.
J Immunol
158:3578, 1997[Abstract]
47.
Warrell RP, de The H, Wang Z, Degos L:
Acute promyelocytic leukemia.
N Engl J Med
329:177, 1993[Free Full Text]
48.
Tobelem G, Jacquillat C, Chastang C, Auclerc MF, Lechevallier T, Weil M, Daniel MT, Flandrin G, Harrouseau JL, Schaison G, Boiron M, Bernard J:
Acute monoblastic leukemia: A clinical and biological study of 74 cases.
Blood
55:71, 1980[Abstract/Free Full Text]
49.
Conneally E, Cashman J, Petzer A, Eaves C:
Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice.
Proc Natl Acad Sci USA
94:9836, 1997[Abstract/Free Full Text]
50.
Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ:
Enhanced detection, maintenance and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human Steel factor, interleukin-3 and granulocyte colony-stimulating factor.
Blood
88:3765, 1996[Abstract/Free Full Text]
51.
Larochelle A, Vormoor J, Hanenberg H, Wang JCY, Bhatia M, Lapidot T, Moritz T, Murdoch B, Xiao XL, Kato I, Williams DA, Dick JE:
Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy.
Nat Med
2:1329, 1996[Medline]
[Order article via Infotrieve]
52.
Conneally E, Eaves CJ, Humphries RK:
Efficient retroviral-mediated gene transfer to human cord blood stem cells with in vivo repopulating potential.
Blood
91:3487, 1998[Abstract/Free Full Text]
53.
Terpstra W, Rozemuller H, Breems DA, Rombouts EJC, Prins A, Fitzgerald DJP, Kreitman RJ, Wielenga JJ, Ploemacher RE, Lowenberg B, Hagenbeek A, Martens ACM:
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemic cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hematopoietic stem cells.
Blood
90:3735, 1997[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. van der Weide, S. D.P.W.M. de Jonge-Peeters, F. Kuipers, E. G.E. de Vries, and E. Vellenga
Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples
Clin. Cancer Res.,
May 1, 2009;
15(9):
3076 - 3083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Boman and M. S. Wicha
Cancer Stem Cells: A Step Toward the Cure
J. Clin. Oncol.,
June 10, 2008;
26(17):
2795 - 2799.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Kennedy, F. Barabe, A. G. Poeppl, J. C. Y. Wang, and J. E. Dick
Comment on "Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells"
Science,
December 14, 2007;
318(5857):
1722c - 1722c.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hosen, C. Y. Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. M. Krensky, and I. L. Weissman
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
PNAS,
June 26, 2007;
104(26):
11008 - 11013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bug, K. Schwarz, C. Schoch, M. Kampfmann, R. Henschler, D. Hoelzer, O. G. Ottmann, and M. Ruthardt
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
Haematologica,
April 1, 2007;
92(4):
542 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yalcintepe, A. E. Frankel, and D. E. Hogge
Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice
Blood,
November 15, 2006;
108(10):
3530 - 3537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Hogge, L. Yalcintepe, S.-H. Wong, B. Gerhard, and A. E. Frankel
Variant Diphtheria Toxin-Interleukin-3 Fusion Proteins with Increased Receptor Affinity Have Enhanced Cytotoxicity against Acute Myeloid Leukemia Progenitors
Clin. Cancer Res.,
February 15, 2006;
12(4):
1284 - 1291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Pearce, D. Taussig, K. Zibara, L.-L. Smith, C. M. Ridler, C. Preudhomme, B. D. Young, A. Z. Rohatiner, T. A. Lister, and D. Bonnet
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
Blood,
February 1, 2006;
107(3):
1166 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Taussig, D. J. Pearce, C. Simpson, A. Z. Rohatiner, T. A. Lister, G. Kelly, J. L. Luongo, G.-a. H. Danet-Desnoyers, and D. Bonnet
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
Blood,
December 15, 2005;
106(13):
4086 - 4092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Xu, J. E. Thompson, and M. Carroll
mTOR regulates cell survival after etoposide treatment in primary AML cells
Blood,
December 15, 2005;
106(13):
4261 - 4268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kawagoe and G. C. Grosveld
Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9
Blood,
December 15, 2005;
106(13):
4269 - 4277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. van Rhenen, N. Feller, A. Kelder, A. H. Westra, E. Rombouts, S. Zweegman, M. A. van der Pol, Q. Waisfisz, G. J. Ossenkoppele, and G. J. Schuurhuis
High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival
Clin. Cancer Res.,
September 15, 2005;
11(18):
6520 - 6527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tavor, I. Petit, S. Porozov, P. Goichberg, A. Avigdor, S. Sagiv, A. Nagler, E. Naparstek, and T. Lapidot
Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice
Blood,
September 15, 2005;
106(6):
2120 - 2127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Thanopoulou, J. Cashman, T. Kakagianne, A. Eaves, N. Zoumbos, and C. Eaves
Engraftment of NOD/SCID-{beta}2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome
Blood,
June 1, 2004;
103(11):
4285 - 4293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tavor, I. Petit, S. Porozov, A. Avigdor, A. Dar, L. Leider-Trejo, N. Shemtov, V. Deutsch, E. Naparstek, A. Nagler, et al.
CXCR4 Regulates Migration and Development of Human Acute Myelogenous Leukemia Stem Cells in Transplanted NOD/SCID Mice
Cancer Res.,
April 15, 2004;
64(8):
2817 - 2824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Monaco, M. Konopleva, M. Munsell, C. Leysath, R.-Y. Wang, C. E. Jackson, M. Korbling, E. Estey, J. Belmont, and M. Andreeff
Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient Survival
Stem Cells,
March 1, 2004;
22(2):
188 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Guan, B. Gerhard, and D. E. Hogge
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)
Blood,
April 15, 2003;
101(8):
3142 - 3149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Feuring-Buske, A. E. Frankel, R. L. Alexander, B. Gerhard, and D. E. Hogge
A Diphtheria Toxin-Interleukin 3 Fusion Protein Is Cytotoxic to Primitive Acute Myeloid Leukemia Progenitors But Spares Normal Progenitors
Cancer Res.,
March 1, 2002;
62(6):
1730 - 1736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Dialynas, L.-e. Shao, G. F. Billman, and J. Yu
Engraftment of Human T-Cell Acute Lymphoblastic Leukemia in Immunodeficient NOD/SCID Mice Which Have Been Preconditioned by Injection of Human Cord Blood
Stem Cells,
September 1, 2001;
19(5):
443 - 452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C. J. Harrison, K. Wheatley, A. K. Burnett, and A. H. Goldstone
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
Blood,
September 1, 2001;
98(5):
1312 - 1320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Wulf, R.-Y. Wang, I. Kuehnle, D. Weidner, F. Marini, M. K. Brenner, M. Andreeff, and M. A. Goodell
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
Blood,
August 15, 2001;
98(4):
1166 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Feuring-Buske and D. E. Hogge
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38{-} progenitor cells from patients with acute myeloid leukemia
Blood,
June 15, 2001;
97(12):
3882 - 3889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Dialynas, M.-J. Lee, D. P. Gold, L.-e. Shao, A. L. Yu, M. J. Borowitz, and J. Yu
Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice
Blood,
May 15, 2001;
97(10):
3218 - 3225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Car and V. M. Eng
Special Considerations in the Evaluation of the Hematology and Hemostasis of Mutant Mice
Vet. Pathol.,
January 1, 2001;
38(1):
20 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
TOP
ABSTRACT
INTRODUCTION